News

The trial design is currently being discussed with the FDA, with trial commencement expected to begin by the end of 2005. “We are very pleased to be selected

A program to develop recombinant vaccines for plague and botulinum neurotoxin serotypes A and B, and a program to develop a vaccine for Venezuelan equine encephalitis have received

Aventis’ main patent protection for Arava expired in September 2003 and a pediatric exclusivity on Arava expired in March 2004. There are other exclusivities related to the drug

The transaction provides MedImmune with three preclinical stage programs developing monoclonal antibodies that target the B-cell antigens CD19, CD20 and CD22. These antigens are believed to play important

This is the final milestone payment in Unigene’s exclusive US licensing agreement with Upsher-Smith. Fortical, Unigene’s first US product, was approved and launched last month and is currently

Vicuron is a biopharmaceutical company focused on the development of novel infection fighters for both hospital-based and community-acquired infections. Through the transaction, Pfizer has acquired two new product

The FDA recommendations were made under the special protocol assessment (SPA), a process in which the FDA evaluates phase III clinical trials and gives assurances that the design

Priority review designation essentially fast tracks the approval process for investigational agents that address unmet medical needs. Based on this designation, the FDA reviews the application with a

The committee voted ten to three to recommend the drug to be used in combination with gemcitabine in patients who have not received previous chemotherapy. Tarceva, which is